Lead Product(s) : Zatolmilast
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Jordan’s Guardian Angels
Deal Size : Undisclosed
Deal Type : Collaboration
Shionogi, Jordan’s Guardian Angels Begin Jordan’s Syndrome Drug Study
Details : The collaboration aims to advance the clinical development of BPN14770 (zatolmilast), which is being evaluated in the mid-stage clinical trial studies for the treatment of Jordan's Syndrome.
Product Name : BPN14770
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 04, 2025
Lead Product(s) : Zatolmilast
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Jordan’s Guardian Angels
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Tamibarotene
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : DCI Partners
Deal Size : $16.7 million
Deal Type : Series B Financing
Rege Nephro Completes Series B Funding For Kidney Disease Therapy Trials
Details : The funds will be used to advance the clinical trials of RN-014 (tamibarotene), company's retinoic acid receptor (RAR) agonist treatment, in Phase 2 for Autosomal Dominant Polycystic Kidney Disease.
Product Name : RN-014
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Undisclosed
July 10, 2024
Lead Product(s) : Tamibarotene
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : DCI Partners
Deal Size : $16.7 million
Deal Type : Series B Financing
Lead Product(s) : Tamibarotene
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rege Nephro Enrolls Patients For Phase II Tamibarotene ADPKD Trial
Details : RN-014 (tamibarotene), under development for ADPKD, is a retinoic acid receptor (RAR) agonist expected to potently inhibit cyst formation and improve renal function.
Product Name : RN-014
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
May 28, 2024
Lead Product(s) : Tamibarotene
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Umedaptanib Pegol
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
RIBOMIC Shows Positive Results in Achondroplasia with Umedaptanib Pegol
Details : RBM-007 (umedaptanib pegol) is a novel oligonucleotide-based aptamer, with potent anti-FGF2 activity and is expected to treat Achondroplasia in pediatrics.
Product Name : RBM-007
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
May 11, 2024
Lead Product(s) : Umedaptanib Pegol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Umedaptanib Pegol
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
RIBOMIC Completes Enrollment in Early Phase 2 Achondroplasia Study
Details : RBM-007 (umedaptanib pegol) is a novel oligonucleotide-based aptamer, with potent anti-FGF2 activity and is expected to treat Achondroplasia.
Product Name : RBM-007
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
March 08, 2024
Lead Product(s) : Umedaptanib Pegol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Risdiplam
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Chugai Files for Evrysdi Additional Indication for Pre-Symptomatic SMA in Infants-2 Months
Details : Evrysdi (risdiplam) is a survival of motor neuron 2 (SMN2) splicing modifier, which is being evaluated for the treatment of infants with pre-symptomatic spinal muscular atrophy.
Product Name : Evrysdi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2024
Lead Product(s) : Risdiplam
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fazirsiran
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Arrowhead Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TAK-999 (fazirsiran) is a potential first-in-class investigational RNA interference (RNAi) therapy designed to reduce the production of mutant alpha-1 antitrypsin protein (Z-AAT) as a potential treatment for the rare genetic liver disease associated with...
Product Name : TAK-999
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
September 01, 2023
Lead Product(s) : Fazirsiran
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Arrowhead Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : N-Acetyl-D-Leucine
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Sanford Burnham Prebys
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DS-1211 is a potent and specific small-molecule inhibitor of TNAP. In vitro studies characterized the mode of inhibition and inhibitory effects of DS-1211 on three human ALP isozymes-TNAP, human intestinal ALP, human placental ALP.
Product Name : DS-1211
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 12, 2022
Lead Product(s) : N-Acetyl-D-Leucine
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Sanford Burnham Prebys
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Maralixibat
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Mirum Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Takeda will be responsible for regulatory approval and commercialization of maralixibat in Japan. Takeda will also be responsible for development, including conducting clinical studies in cholestatic indications.
Product Name : LUM001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 21, 2021
Lead Product(s) : Maralixibat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Mirum Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement